Pharmaceutical Products Companies By Pb Ratio

Price To Book
Price To BookEfficiencyMarket RiskExp Return
1VRCA Verrica Pharmaceuticals
238.54
(0.03)
 9.64 
(0.32)
2HURA TuHURA Biosciences
195.89
 0.05 
 10.61 
 0.58 
3DRUG Bright Minds Biosciences
70.58
 0.15 
 126.69 
 18.72 
4VNRX Volitionrx
38.44
 0.02 
 5.92 
 0.12 
5VRNA Verona Pharma PLC
24.85
 0.22 
 2.90 
 0.63 
6DRRX Durect
22.45
(0.14)
 4.84 
(0.67)
7VSTM Verastem
21.49
 0.23 
 6.16 
 1.43 
8TLX Telix Pharmaceuticals Limited
21.03
 0.29 
 2.55 
 0.74 
9DYAI Dyadic International
14.83
 0.10 
 5.55 
 0.56 
10VCEL Vericel Corp Ord
11.15
 0.11 
 2.89 
 0.31 
11VERA Vera Therapeutics
10.9
 0.13 
 3.79 
 0.48 
12ELTX Elicio Therapeutics
10.11
 0.11 
 4.81 
 0.54 
13VRTX Vertex Pharmaceuticals
7.71
(0.01)
 1.67 
(0.01)
14VCNX Vaccinex
7.34
(0.02)
 8.74 
(0.17)
15VKTX Viking Therapeutics
6.47
(0.01)
 4.99 
(0.03)
16DMAC DiaMedica Therapeutics
5.04
 0.19 
 3.43 
 0.64 
17ELVN Enliven Therapeutics
4.13
 0.07 
 2.79 
 0.18 
18ELDN Eledon Pharmaceuticals
3.66
 0.19 
 4.92 
 0.95 
19VIRX Viracta Therapeutics
3.0
(0.18)
 4.22 
(0.75)
20VTVT vTv Therapeutics
2.79
 0.04 
 4.14 
 0.15 
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities. Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.